Moreover, the selective pressure of the CD19-directed treatment increases the incidence of the so-called lineage switch [13,14], which has become one of the possible mechanisms of BCP-ALL resistance to immunotherapy. Here, CD19 is linked to acute lymphoblastic leukemia.